Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.

导出 OA

翻译打印收藏纠错

作者： Tadao,Ishida ^[1] ; Shigeki,Ito ^[2] ; Junji,Tanaka ^[3] ; Michihiro,Uchiyama ^[4] ; Yawara,Kawano ^[5] ; Philippe,Moreau ^[6] ; Thomas,Martin ^[7] ; Marie-Laure,Risse ^[8] ; Keisuke,Tada ^[9] ; Kenshi,Suzuki ^[10] ; Kenichi,Ishizawa ^[11]

作者单位： Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan. ^[1] Division of Hematology & Oncology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan. ^[2] Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan. ^[3] Department of Hematology, Japanese Red Cross Society, Suwa Hospital, Suwa, Japan. ^[4] Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan. ^[5] Department of Hematology, University Hospital of Nantes, Nantes, France. ^[6] Department of Medicine, University of California, San Francisco, CA, USA. ^[7] Sanofi, Research and Development, Vitry-Sur-Seine, France. ^[8] Sanofi, Research and Development, Tokyo, Japan. ^[9] Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan. ^[10] Department of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan. ^[11]

主题词人类(Humans);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);地塞米松(Dexamethasone);日本(Japan);多发性骨髓瘤(Multiple Myeloma)

DOI 10.1093/jjco/hyac137

PMID 36073950

发布时间 2022-12-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交